"All data on the clinical trials of Sputnik V have been provided, the GCP (Good Clinical Practice) inspection has been completed and a positive review has been received from the European Medicines Agency based on its results," the fund said in its Telegram message.
It is clarified that the examination of the drug is ongoing, there are no delays in the procedure.
"Although the decision on the timing of the procedure is the prerogative of the EMA, the Sputnik V team expects to receive a vaccine registration within two months," added the RDIF.
Earlier, Russian President Vladimir Putin said that delaying the registration of Sputnik V in the European Union is a tool for ensuring commercial interests.
The RDIF also noted that the fund did not receive critical comments from EMA as part of the registration procedure for Sputnik V.
At the end of April, the regulator completed the first stage of the drug examination.